Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Pain, Postoperative 1Pain 1Multiple Myeloma 1Mucositis 1Lymphoma 1Head and Neck Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

Cisplatin 47Radiotherapy 37Fluorouracil 23Cetuximab 17pembrolizumab 11Carboplatin 11Paclitaxel 8Docetaxel 8Radiotherapy, Intensity-Modulated 6Chemotherapy, Adjuvant 6Surgical Procedures, Operative 5Standard of Care 5nimotuzumab 4Methotrexate 4Gabapentin 4Drug Therapy 4Afatinib 4Radiotherapy, Conformal 3Radiation 3Porfiromycin 3Nivolumab 3Neoadjuvant Therapy 3Fibroblast Growth Factor 7 3Bleomycin 3zalutumumab 2sargramostim 2epacadostat 2Tranexamic Acid 2Tirapazamine 2Pilocarpine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Head and Neck Neoplasms × oxycodone-acetaminophen × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡